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Serum Prolactin and Bone Mineral Density in Schizophrenia: 
A Systematic Review
John Lally1,2,3,4, Abdullah Bin Sahl2, Kieran C. Murphy2, Fiona Gaughran1,5, Brendon Stubbs6,7
Departments of 1Psychosis Studies and 6Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 
London, UK, 2Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, 3Department of Psychiatry, School of 
Medicine and Medical Sciences, University College Dublin, 4St Vincent’s Hospital Fairview, Dublin, Ireland, 5National Psychosis Service and 
7Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK
The relationship between serum prolactin and bone mineral density (BMD) in schizophrenia is unclear. We conducted 
a literature review of databases from inception until December 2018 for cross-sectional, case-control, prospective and 
retrospective studies analyzing correlations between serum prolactin and BMD measured using dual energy X-ray ab-
sorptiometry or quantitative ultrasound at any skeletal site in people with schizophrenia. Data was summarized with 
a best evidence synthesis. This review identified 15 studies (1 longitudinal study, 10 cross-sectional and 4 case-control 
studies; 1,360 individuals with a psychotic disorder; mean age 45.1 ± 9.4 [standard deviation] years, female 742 
[54.6%], mean illness duration 17.7 ± 11.3 years) assessing the relationship between serum prolactin and BMD in 
schizophrenia. There was a statistically significant inverse correlation between serum prolactin and BMD identified in 
eight of the studies (53% of all studies), suggesting mixed evidence for an association between serum prolactin and 
BMD. Of those studies which identified a significant inverse correlation between serum prolactin and BMD (n = 5), 
152 (52.1%) of patients were treated with prolactin raising antipsychotics, compared to 197 (48.1%) of patients in 
those studies which did not identify a significant correlation between prolactin and BMD. Available studies cannot 
resolve the link between excess prolactin and reduced BMD in schizophrenia. Future studies should be longitudinal 
in design and combine measures of serum prolactin along with other risk factors for reduced BMD such as smoking 
and vitamin D and sex hormone levels in assessing the relationship between prolactin and BMD in schizophrenia. 
KEY WORDS: Psychotic disorders; Hyperprolactinemia; Hormones; Fracture; Bone density.
INTRODUCTION
Osteoporosis is a progressive disease characterised by a 
marked bone loss, disruption in the microstructure of 
bone tissue, and deterioration of the skeletal structure.1) 
Worldwide, 200 million people are estimated to have 
osteoporosis.2) Osteoporosis and low bone mineral den-
sity (BMD) are associated with an increased fracture risk.1) 
The fragility factors resulting from reduced BMD and os-
teoporosis significantly impair quality of life and are asso-
ciated with increased morbidity and mortality.3)
People with schizophrenia are two and a half times 
more likely to have osteoporosis4) and have a 70% in-
creased fracture risk compared to healthy general pop-
ulation controls.5) However, risk factors for osteoporosis 
and fractures in psychotic disorders are not well defined. 
In a meta-analysis of BMD in established psychosis, hy-
perprolactinemia ( = −0.0102; 95% confidence interval 
[CI], −0.0135 to −0.0068; p ＜ 0.0001) and smoking ( = 
−0.0099; 95% CI, −0.0185 to −0.0012; p = 0.02) were 
significant moderators of low bone mass at the lumbar 
spine.6) Whilst this meta-analysis was helpful, we re-
stricted our inclusion criteria to those studies which pro-
vided BMD measures at the lumbar spine or hip region. In 
doing so, there are several studies evaluating the effects of 
prolactin on BMD in psychotic disorders, which were 
excluded. 
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High rates of hyperprolactinaemia are found in the ear-
ly stages of psychotic disorders; with 43% with hyper-
prolactinaemia at time of first contact for psychosis, and 
27% at 12 months follow up.7) Prevalence rates for hyper-
prolactinaemia with antipsychotic use in multi episode 
schizophrenia across various clinical trials range from 
28% to 69%.8) Epidemiological studies have reported 
conflicting effects of hyperprolactinaemia on fracture risk 
in schizophrenia, with some reporting an increased risk 
with prolactin raising (PRL-R) antipsychotics compared to 
prolactin spearing (PRL-S),9,10) while others have not iden-
tified a differentiating effect by PRL-R or PRL-S anti-
psychotics on the fracture risk.11-13) A Norwegian popula-
tion nationwide population cohort study over a six-year 
period, identified 39,938 people who experienced a hip 
fracture. This study found that an increased risk of hip 
fracture was associated with any antipsychotic exposure 
(standardized incidence ratio [SIR] = 2.1; 95% CI, 1.9−
2.1), first-generation antipsychotics (FGAs; SIR = 2.0; 95% 
CI, 1.8−2.2), second-generation antipsychotics (SGAs; 
SIR = 2.2; 95% CI, 1.9−2.4), prolactin-sparing anti-
psychotics (SIR = 2.4; 95% CI, 1.8−3.1) and prolactin-el-
evating antipsychotics (SIR = 2.0; 95% CI, 1.9−2.2).14)
A previous narrative review indicated that associations 
between antipsychotic induced prolactin and reduced 
BMD in schizophrenia remains inconclusive, though with 
some evidence to support a stronger association in older 
men and postmenopausal women.15) In a meta-analysis of 
7 studies16-22) by Tseng et al.,23) 304 people with schizo-
phrenia in receipt of PRL-R antipsychotics, and 212 treat-
ed with PRL-S antipsychotics were identified.23) The BMD 
in those treated with PRL-R antipsychotics was sig-
nificantly lower than in those receiving PRL-S (effect size = 
−0.410, 95% CI¼, −0.703 to −0.117, p = 0.006). 
However, in meta-regression analysis, serum prolactin 
levels were not a moderator of reduced BMD (p = 0.456; 
though only 5 studies with serum prolactin measures were 
included). 
To clarify the relationship between serum prolactin lev-
els and BMD in schizophrenia we performed a systematic 
review of studies examining for correlations between se-
rum prolactin and BMD in psychotic disorders. A pre-
vious review provided data on the proportion of studies 
reporting associations between prolactin, hyperprolac-
tinaemia or use of PRL-R antipsychotics and osteoporosis, 
but did not specify studies which reported associations 
between serum prolactin levels and reduced BMD.24)
METHODS
This systematic review adhered to the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) guide-
lines25) and PRISMA statement.26)
Inclusion and Exclusion Criteria
Included in the review were: (1) observational studies 
of cross sectional, case-control, prospective, and retro-
spective design were included, involving adults (aged 18 
years or more) with a diagnosis of schizophrenia or schiz-
oaffective disorder or a related psychotic disorder, ac-
cording to Diagnostic and Statistical Manual of Mental 
Disorder (DSM)27) or International Classification of Dis-
eases (ICD) classification28); (2) Studies measuring and re-
porting BMD via dual energy X-ray absorptiometry (DXA) 
and/or quantitative ultrasound (QUS) scanning and serum 
prolactin levels a patient group with a confirmed diag-
nosis of schizophrenia or other psychotic disorder were 
included; (3) studies published in peer-reviewed journals 
and with no language restrictions.
Studies were excluded if they did not provide sufficient 
data: (1) to ascertain BMD values; or (2) serum prolactin 
levels; or (3) the study assessed the association between 
serum prolactin and BMD but did not provide prolactin 
and/or BMD values; and (4) if they were review articles or 
case reports.
Information Sources and Searches
Literature search and study selection
Two independent authors (JL and ABS) systematically 
searched, Medline, PubMed, Scopus, Embase, and 
PsycINFO from database inception until December 2018 
using the following search terms: (osteoporosis or osteo-
penia or osteo* or BMD or DXA or DEXA) and (schizo-
phrenia or schizo* or psychosis or antipsychotics) and 
prolactin, with removal of duplicate articles. The elec-
tronic search was supplemented by a manual review of 
reference lists from eligible publications. The correspond-
ing authors of research groups were contacted where ad-
ditional information was necessary.
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Study Selection
Two authors (JL and ABS) independently searched 
through titles, abstracts and full-text articles for review. 
The two authors applied the eligibility criteria, and a list of 
full text articles was developed through consensus. 
Articles deemed viable were cross-checked by both au-
thors and an independent author (BS) to ensure that they 
met the inclusion criteria.
The two reviewers then considered the full text of these 
articles, and a final list of included articles was reached 
through consensus.
We included studies which assessed the relationship 
between serum prolactin levels and BMD and provided 
comparisons by correlational analysis between BMD and 
prolactin levels in patients with schizophrenia or other 
psychotic disorders. 
Outcome Measures
We performed a search for studies having examined as-
sociations between prolactin and BMD in psychotic 
disorders.
The primary outcome was relationship between serum 
prolactin and BMD captured by DXA scans or QUS in 
schizophrenia. The more portable nature of QUS scan-
ners may make it an appropriate method of evaluating 
BMD in large populations.29) QUS provides a different 
measure of bone structure to DXA scans, but with close 
relationship in measurements between both tools.30,31)
The data were collected as T scores, which compare 
the measured BMD with the mean for a young adult of 
that gender, or z scores, which compare the measured 
BMD with that of an age- and gender matched mean 
value. For studies which reported both T and z scores, we 
used the T score as recommended by the World Health 
Organization to better predict risk of fracture.32,33) We 
used z scores when it was the only measure reported. We 
included BMD measurements expressed as absolute raw 
levels (g/cm2), when this was the only BMD measure com-
pared to serum prolactin levels.
We extracted data on sample size, and serum prolactin 
levels (mIU/L). We measured serum prolactin levels in 
mIU/L, but have also presented data in ng/ml, calculated 
on the basis of 1 ng/ml equaling 21.2 mIU/L.8) 
We extracted data on PRL-R and PRL-S antipsychotics. 
Antipsychotics with a PRL-R effect included amisulpride, 
risperidone, paliperidone and FGAs, with the PRL-S anti-
psychotics including olanzapine, quetiapine and aripi-
prazole. 
For studies, which used the same sample group of pa-
tients at a different point in time, we used data from the 
study with the largest data set.
Data Extraction 
Two authors (ABS and JL) extracted data from the rele-
vant studies. Additionally, we extracted further data 
where possible to assess the study-level factors associated 
with BMD, in patients. The data collected from each ar-
ticle included: study design, geographical location, study 
setting, method of BMD assessment, skeletal site for BMD 
assessment, and details of study participants (sample size, 
number of cases [and controls], mean age, and sex), mean 
serum orolactin concentrations of the study sample, num-
ber with hyperprolactinaemia, proportion treated with 
PRL-R and PRL-S antipsychotics, first episode psychosis 
(yes or no), psychotic disorder type (schizophrenia, schiz-
oaffective disorder, psychosis or other [specified]) and du-
ration of illness.
The data were collected in a predetermined database.
Data Analysis
We assessed correlations between serum prolactin lev-
els and BMD levels. In our study negative correlation in-
dicates that higher serum prolactin associates with re-
duced BMD. 
Information on all reported significant and non-sig-
nificant correlates of serum prolactin levels and BMD in 
psychotic disorders were collated (as defined by primary 
author’s papers). To assess the effect and direction of the 
relationship between serum prolactin and BMD, we 
sought to standardize the statements about statistical sig-
nificance in line with guidance from the Canadian Agency 
for Drugs and Technology in Health (https://www.cadth. 
ca/interventions-directed-professionals).34)
For this study the categories were defined as the follow-
ing: 0% of studies found a significant association between 
serum prolactin levels and BMD = no evidence for an as-
sociation; 1% to 33% of studies found a significant associ-
ation = largely no evidence for an association; 34% to 
66% of studies found a significant association = mixed 
evidence for an association; more than 67% of studies 
found a significant association = good to strong evidence 
of an association.
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Fig. 1. Flowchart of the article 
selection process in a systematic re-
view of associations between serum 
prolactin and bone mineral density 
in psychotic disorders.
We analyzed the relationship between PRL-R and 
PRL-S antipsychotics and BMD, and correlations between 
serum prolactin and BMD. 
Data Synthesis 
The review is presented in a best evidence synthesis.
RESULTS
The systematic review identified 519 studies and after 
the removal of duplicates and screening, 15 stud-
ies16,18,22,35-46) met our inclusion criteria for assessing the 
relationship between serum prolactin and BMD (Fig. 1). 
Full details of the included studies are shown in Table 1.
Across the 15 studies, there were 1,360 individuals 
with a psychotic disorder (100% with a schizophrenia di-
agnosis). The mean age was 45.1 years (standard devia-
tion [SD], 9.4 years) (range, 34−61 years), 742 (54.6%) 
were female, with a mean illness duration of 17.7 years 
(SD, 11.3 years) (range, 1−35 years). There was 1 longi-
tudinal study (total cases, 163), 10 cross-sectional studies 
(n = 959) and 4 case-control studies (total cases, 238). 
Five of the studies were conducted in inpatient settings, 1 
in an outpatient setting and two in a mix of in- and out-
patient settings. Seven of the studies were conducted in 
Asia, four in Europe and one from each of North America, 
South America, the Middle East, and Australia. 
The mean serum prolactin level across all studies was 
773.5 IU/L (SD, 317.5 IU/L) (range, 244.0−1,628 IU/L). 
All of the included studies measured BMD. Twelve 
studies measured BMD using DXA (n = 1,080), and three 
used QUS (n = 280) to measure BMD. Eight studies used T 
scores to quantify BMD, while 5 used z scores, and 2 stud-
ies measured BMD in g/cm2 (n = 1 study measured g/cm2 
only). Eleven of the studies provided BMD measures at the 
spine or hip. And six measured BMD at the hand/radius (n = 
4) or calcaneus (n = 2). 
Correlates of Prolactin and BMD
There was a statistically significant inverse correlation 
between higher serum prolactin and BMD identified in 
eight of the studies.18,22,35,37,40,42,44,46) The remaining 7 
studies showed no significant correlation between serum 
prolactin and BMD.16,36,38,39,41,43,45) 
Fifty-three percent of studies identified a significant in-
verse correlation between serum prolactin and BMD in 
psychotic disorders, suggesting mixed evidence for an as-
sociation between serum prolactin and BMD.
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Table 2. Comparison between studies with positive (n = 8) and nega-
tive (n = 7) correlation between serum prolactin and bone mineral 
density
Positive/negative 
correlation 
studies (n)
Prolactin 
(ng/ml)* T value p value
Mean number 
of cases
No (7)
Yes (8)
82.1 ± 22.8
98.1 ± 81.2
−0.502 0.624
Mean age No (7)
Yes (7)
44.7 ± 8.7
45.6 ± 10.8
−0.158 0.877
Duration of 
illness
No (4)
Yes (5)
19.3 ± 12.6
16.4 ± 11.5
−0.257 0.803
*Mean ± standard deviation.
Table 3. Comparison between methods and quantification of BMD 
measurement and positive/negative correlation between serum 
prolactin and BMD
Measurement Studies with positive correlation, n (%) 
2 value p value
Bone scan
QUS
No 2 (66.7)
Yes 1 (33.3)
DXA 0.603 0.446
No 5 (41.7)
Yes 7 (58.3)
Bone region
Spine/hip
No 4 (40.0)
Yes 6 (60.0) 1.339 0.512
Hand/radius
No 2 (50.0)
Yes 2 (50.0)
BMD measurement
T score
No 3 (37.5)
Yes 5 (62.5)
Z score
No 4 (80.0)
Yes 1 (20.0)
BMD (g/cm2) 4.252 0.119
No 0 (0)
Yes 2 (100)
BMD, bone mineral density; QUS, quantitative ultrasound; DXA, 
dual energy X-ray absorptiometry. 
Studies with significant correlation between serum pro-
lactin and reduced BMD (n = 8) and those with absence of 
a significant correlation between the measures (n = 7) did 
not differ in mean age, mean duration of illness or in the 
method of measurement or quantification of BMD (Tables 
2 and 3). 
Ten of the included studies documented the proportion 
of patients treated with PRL-R or PRL-S antipsychotics. Of 
those studies which identified a significant inverse corre-
lation between serum prolactin and BMD (n = 
5),18,22,37,40,46,47) 152 (52.1%) of patients were treated with 
PRL-R antipsychotics, compared to 197 (48.1%) of pa-
tients in those studies which did not identify a significant 
correlation between prolactin and BMD.16,38,39,41,45) 
Narrative Results
Only one of the included studies was of longitudinal 
design. This prospective study from Wang et al.35) in 163 
people with first episode psychosis found that the reduc-
tion in BMD at 12 months in those treated with FGAs was 
significantly negatively correlated with serum prolactin 
levels. However, there was no correlation between pro-
lactin and BMD in the SGA group. 
Five cross sectional studies identified significant corre-
lations between serum prolactin levels and low BMD in 
schizophrenia. In the largest cross sectional study, 219 
Chinese, postmenopausal female inpatients with schizo-
phrenia (mean age [SD], 60.4 years [7.0 years]) were 
found to have a significant inverse correlation between 
serum prolactin and BMD.42) They further identified a re-
lationship between duration of antipsychotic use and re-
duced BMD. A cross sectional study of 51 patients with 
schizophrenia (30 males and 21 females; mean age, 39.0 
years) treated with haloperidol monotherapy for 2 years or 
more found no evidence of an overall association be-
tween serum prolactin and BMD loss (t scores) or actual 
bone density (g/cm2).40) However, 94.4% (17/18) of the fe-
male patients with BMD loss had hyperprolactinaemia, of 
whom 7 showed concurrent hypoestrogenism, and serum 
prolactin levels were significantly higher in female pa-
tients with BMD loss (low t score) as compared to those 
with normal BMD (normal t score) ( 72.5 ± 49.7 ng/ml vs. 
42.1 ± 31.2 ng/ml; p = 0.043).40) 
Inconsistent findings have been reported in the liter-
ature in relation to gender in the context of prolactin’s ef-
fect on BMD. No associations were found between serum 
prolactin and BMD in women in 4 studies.18,19,21,36) In the 
cross sectional study of Rey-Sánchez et al.,44) 48 male 
(mean age, 61.9 years) and 25 postmenopausal female 
(mean age, 59.8 years) patients with chronic schizo-
phrenia were assessed. There was significant negative 
correlation between bone mass and prolactin levels in fe-
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male, but not in male patients treated with FGAs. 
Contrasting findings were seen in a later study of 195 peo-
ple with schizophrenia (80 males and 115 females),22) in 
which hyperprolactinaemia was associated with a lower 
DXA t score in men, but not in women. 
Two cross sectional studies of male only patients, did 
not identify significant correlations between serum pro-
lactin and reduced BMD.16,41) The study from Kishimoto et 
al.41) identified a relationship between duration of anti-
psychotic treatment and reduced BMD in the subset of pa-
tients with high hyperprolactinaemia.
Only one study identified consistent associations be-
tween prolactin concentration and reduced BMD at mul-
tiple bone sites.46) This study of 16 people with schizo-
phrenia found statistically significant correlations be-
tween increased serum prolactin and were reduced BMD 
at the femoral neck (p ＜ 0.01), trochanter (p ＜ 0.01), 
Ward’s triangle (p ＜ 0.05) and total BMD (p ＜ 0.05). 
Lumbar spine BMD was not correlated with prolactin 
levels.
DISCUSSION
In this systematic review of serum prolactin and BMD 
in psychotic disorders, the evidence for an association 
with reduced BMD in psychosis remains mixed. Large 
scale epidemiological studies have indicated an associa-
tion between the use of PRL-R antipsychotics and frac-
tures, though the exact relationship between raised serum 
prolactin and effects on BMD remains elusive. Epidemio-
logical studies have reported conflicting effects of hyper-
prolactinaemia on fracture risk in schizophrenia, with 
some reporting an increased risk with PRL-R anti-
psychotics compared to PRL-S antipsychotics,9,10) while 
others have not identified a differentiating effect by PRL-R 
or PRL-S antipsychotics on the fracture risk.11-13) The 
meta-analysis from Tseng et al.23) found evidence of re-
duced BMD in those treated with PRL-R antipsychotic 
compared to PRL-S antipsychotics.
From the evidence in this review, it is not possible to 
conclude that contemporaneous serum prolactin levels 
alone are consistently associated with reduced BMD in 
psychotic disorders. It may be the case that other features 
such as hypogonadism48) are required to increase the risk 
for reduced BMD with elevated serum prolactin levels.49) 
Other risk factors associated with reductions in BMD such 
as vitamin D deficiency,50-52) obesity,53,54) and smok-
ing55,56) are prevalent in psychotic disorders, and may fur-
ther contribute to low BMD.
The paucity of longitudinal studies is a limitation. All 
but one of the studies35) were cross-sectional in design, 
and this longitudinal study was to only one to investigate 
the association between serum prolactin and BMD in first 
episode schizophrenia. This study identified an inverse 
correlation between serum prolactin levels and reduced 
BMD in those treated with FGAs raising the possibility of a 
relationship between sustained excess prolactin and re-
ductions in BMD.35) 
Given the high rates of hyperprolactinaemia seen in the 
early stages of psychosis,7) and that hyperprolactinaemia 
and elevated prolactin secretion occurs more frequently 
in antipsychotic naïve schizophrenia patients than con-
trols,57) more prospective studies in early psychosis pop-
ulations may help clarify the relationship between pro-
lactin and BMD identify risk factors without the con-
founding influence of antipsychotic medication.
Data in the majority of primary studies was not pre-
sented in a format that allowed a more complete data ex-
traction of variables such as stage of illness, or duration of 
treatment. Further, the lack of longitudinal information on 
the relationship between serum prolactin levels, and life-
time antipsychotic use is a limitation in our ability to ex-
amine the enduring effects of raised prolactin levels and 
antipsychotic use on BMD. 
Four of the included studies measured BMD using QUS 
(including one which used both DXA and QUS). The QUS 
is increasingly recognized as a valid alternative to DXA,58) 
but conclusive evidence supporting this is lacking- specif-
ically that it lacks sensitivity and specificity when com-
pared with DXA and so it cannot be used as a direct alter-
native to DXA scanning.59) However, we did not identify a 
significantly increased number of studies with significant 
correlations between serum prolactin and reduced BMD 
in studies using DXA scanning compared to those using 
QUS. 
The mean age of this patient group was 45 years with 
little inclusion of older patients, which is not representa-
tive of the general patient population. However, the mean 
age in our study was higher than that identified in a pre-
vious review and meta-analyses of the relationship be-
tween schizophrenia and skeletal site specific reduced 
BMD (average age, 34 years) in schizophrenia6) and is 
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similar to the average age in the meta-analysis of Tseng et 
al.23) in which PRL-R antipsychotic use was associated 
with reduced BMD. 
CONCLUSION
Further work is required to elucidate the nature of the 
relationship between serum prolactin excess and BMD in 
psychotic disorders. There is mixed evidence to date to 
support a significant relationship between contempora-
neous raised prolactin and reductions in BMD. It is likely 
that other factors such as hypogonadism relating to excess 
prolactin and other risk factors such as smoking and vita-
min D deficiency contribute to the reductions in BMD 
seen in psychotic disorders. Studies that include all these 
considerations should be able to evaluate the differential 
weight of factors contributing to BMD reductions in schiz-
ophrenia and other psychotic disorders. 
Fiona Gaughran and Brendon Stubbs are, in part, fund-
ed by the National Institute for Health Research 
Collaboration for Leadership in Applied Health Research 
& Care Funding scheme with support from the National 
Institute for Health Research (NIHR) Biomedical Research 
Centre at South London and Maudsley NHS Foundation 
Trust. The views expressed in this publication are those of 
the authors and not necessarily those of the National 
Health Service (NHS), the National Institute for Health 
Research (NIHR) or the Department of Health and Social 
Care. 
Fiona Gaughran has received honoraria for advisory 
work and lectures or CME activity support from Roche, 
BMS, Lundbeck, Otsuka, Janssen and Sunovion, is a col-
laborator on a NHS Innovations project co-funded by 
Janssen and has a family member with professional links 
to Lilly and GSK, including shares. All other authors de-
clare they have no conflict of interest. 
REFERENCES
1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture 
risk. Lancet 2002;359:1929-1936.
2. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the eld-
erly: a world-wide projection. Osteoporos Int 1992;2:285- 
289.
3. Riggs BL, Melton LJ 3rd. The worldwide problem of osteopo-
rosis: insights afforded by epidemiology. Bone 1995;17(5 
Suppl):505S-511S.
4. Stubbs B, De Hert M, Sepehry AA, Correll CU, Mitchell AJ, 
Soundy A, et al. A meta-analysis of prevalence estimates and 
moderators of low bone mass in people with schizophrenia. 
Acta Psychiatr Scand 2014;130:470-486.
5. Stubbs B, Gaughran F, Mitchell AJ, De Hert M, Farmer R, 
Soundy A, et al. Schizophrenia and the risk of fractures: a sys-
tematic review and comparative meta-analysis. Gen Hosp 
Psychiatry 2015;37:126-133.
6. Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, 
Lally J. Lower bone mineral density at the hip and lumbar 
spine in people with psychosis versus controls: a compre-
hensive review and skeletal site-specific meta-analysis. Curr 
Osteoporos Rep 2016;14:249-259.
7. Lally J, Ajnakina O, Stubbs B, Williams HR, Colizzi M, Carra 
E, et al. Hyperprolactinaemia in first episode psychosis - a lon-
gitudinal assessment. Schizophr Res 2017;189:117-125.
8. Bushe C, Shaw M, Peveler RC. A review of the association be-
tween antipsychotic use and hyperprolactinaemia. J 
Psychopharmacol 2008;22(2 Suppl):46-55.
9. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, 
de Vries F. Antipsychotic use and the risk of hip/femur frac-
ture: a population-based case-control study. Osteoporos Int 
2009;20:1499-1506.
10. Howard L, Kirkwood G, Leese M. Risk of hip fracture in pa-
tients with a history of schizophrenia. Br J Psychiatry 2007; 
190:129-134.
11. Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD. Risk 
of low bone mineral density associated with psychotropic 
medications and mental disorders in postmenopausal 
women. J Clin Psychopharmacol 2011;31:56-60.
12. Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, 
Bernabei R, et al. Conventional or atypical antipsychotics and 
the risk of femur fracture among elderly patients: results of a 
case-control study. J Clin Psychiatry 2007;68:929-934.
13. Sørensen HJ, Jensen SO, Nielsen J. Schizophrenia, anti-
psychotics and risk of hip fracture: a population-based 
analysis. Eur Neuropsychopharmacol 2013;23:872-878.
14. Bakken MS, Schjøtt J, Engeland A, Engesaeter LB, Ruths S. 
Antipsychotic drugs and risk of hip fracture in people aged 60 
and older in Norway. J Am Geriatr Soc 2016;64:1203-1209.
15. Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone 
mineral density in patients with schizophrenia: gender 
differences. Clin Psychopharmacol Neurosci 2016;14:238- 
249.
16. Lee TY, Chung MY, Chung HK, Choi JH, Kim TY, So HS. Bone 
density in chronic schizophrenia with long-term anti-
psychotic treatment: preliminary study. Psychiatry Investig 
2010;7:278-284.
17. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, 
■ Acknowledgments
■ Conflicts of Interest
 Prolactin and Bone Density in Schizophrenia 341
Mimura M, et al. The impact of prolactin-raising anti-
psychotics on bone mineral density in patients with schizo-
phrenia: findings from a longitudinal observational cohort. 
Schizophr Res 2013;147:383-386.
18. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss 
M. Risperidone, but not olanzapine, decreases bone mineral 
density in female premenopausal schizophrenia patients. J 
Clin Psychiatry 2003;64:761-766.
19. Meaney AM, O’Keane V. Bone mineral density changes over 
a year in young females with schizophrenia: relationship to 
medication and endocrine variables. Schizophr Res 2007;93: 
136-143.
20. O’Keane V, Meaney AM. Antipsychotic drugs: a new risk fac-
tor for osteoporosis in young women with schizophrenia? J 
Clin Psychopharmacol 2005;25:26-31.
21. Lin CH, Huang KH, Chang YC, Huang YC, Hsu WC, Lin CY, 
et al. Clozapine protects bone mineral density in female pa-
tients with schizophrenia. Int J Neuropsychopharmacol 2012; 
15:897-906.
22. Lin CH, Lin CY, Huang TL, Wang HS, Chang YC, Lane HY. 
Sex-specific factors for bone density in patients with schizo-
phrenia. Int Clin Psychopharmacol 2015;30:96-102.
23. Tseng PT, Chen YW, Yeh PY, Tu KY, Cheng YS, Wu CK. Bone 
mineral density in schizophrenia: an update of current 
meta-analysis and literature review under guideline of 
PRISMA. Medicine (Baltimore) 2015;94:e1967.
24. De Hert M, Detraux J, Stubbs B. Relationship between anti-
psychotic medication, serum prolactin levels and osteopo-
rosis/osteoporotic fractures in patients with schizophrenia: a 
critical literature review. Expert Opin Drug Saf 2016;15:809- 
823.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, 
Rennie D, et al. Meta-analysis of observational studies in epi-
demiology: a proposal for reporting. Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) group. 
JAMA 2000;283:2008-2012.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 
Preferred reporting items for systematic reviews and meta- 
analyses: the PRISMA statement. Ann Intern Med 2009;151: 
264-269, W64.
27. American Psychiatric Association. Diagnostic and statistical 
manual of mental disorders: DSM-IV-TR. 4th ed. Washington 
D.C.:American Psychiatric Association;2000.
28. World Health Organization (WHO). The ICD-10 classi-
fication of mental and behavioural disorders: clinical descrip-
tions and diagnostic guidelines. Geneva:WHO;1992.
29. Frost ML, Blake GM, Fogelman I. Quantitative ultrasound and 
bone mineral density are equally strongly associated with risk 
factors for osteoporosis. J Bone Miner Res 2001;16:406-416.
30. Guglielmi G, de Terlizzi F. Quantitative ultrasond in the as-
sessment of osteoporosis. Eur J Radiol 2009;71:425-431.
31. Robertson A, Godavitarne C, Peters J. Bone quantification. 
Orthop Trauma 2017;31:326-329.
32. World Health Organization. Assessment of fracture risk and 
its application to screening for postmenopausal osteoporosis. 
Report of a WHO study group. World Health Organ Tech Rep 
Ser 1994;843:1-129.
33. Kanis JA. Assessment of fracture risk and its application to 
screening for postmenopausal osteoporosis: synopsis of a 
WHO report. Osteoporos Int 1994;4:368-381.
34. Canadian Agency for Drugs and Technologies in Health 
(CADTH). Interventions directed to professionals [Internet]. 
Ottawa: CADTH; 2011 [cited at 2019 Jan 3]. Available from: 
https://www.cadth.ca/interventions-directed-professionals.
35. Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, et al. Effects of an-
tipsychotics on bone mineral density and prolactin levels in 
patients with schizophrenia: a 12-month prospective study. 
Hum Psychopharmacol 2014;29:183-189.
36. Bergemann N, Parzer P, Mundt C, Auler B. High bone turn-
over but normal bone mineral density in women suffering 
from schizophrenia. Psychol Med 2008;38:1195-1201.
37. Bulut SD, Bulut S, Atalan DG, Tulaci RG, Türker T, Gürçay E, 
et al. The effect of antipsychotics on bone mineral density and 
sex hormones in male patients with schizophrenia. Psychiatr 
Danub 2016;28:255-262.
38. Howes OD, Wheeler MJ, Meaney AM, O’Keane V, Fogelman 
I, Blake G, et al. Bone mineral density and its relationship to 
prolactin levels in patients taking antipsychotic treatment. J 
Clin Psychopharmacol 2005;25:259-261.
39. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, 
Moncayo Naveda RC, et al. Osteoporosis in patients with 
schizophrenia. Am J Psychiatry 2005;162:162-167.
40. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH, et 
al. Prevalence of bone mineral density loss in Korean patients 
with schizophrenia: a cross-sectional study. J Clin Psychiatry 
2006;67:1391-1396.
41. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, 
Kashima H, et al. Antipsychotic-induced hyperprolactinemia 
inhibits the hypothalamo-pituitary-gonadal axis and reduces 
bone mineral density in male patients with schizophrenia. J 
Clin Psychiatry 2008;69:385-391.
42. Liang Y, Huang J, Tian JB, Cao YY, Zhang GL, Wang CG, et al. 
Factors associated with decreased bone mineral density in 
postmenopausal women with schizophrenia. Clin Interv 
Aging 2016;11:153-157.
43. Renn JH, Yang NP, Chou P. Effects of plasma magnesium and 
prolactin on quantitative ultrasound measurements of heel 
bone among schizophrenic patients. BMC Musculoskelet 
Disord 2010;11:35.
44. Rey-Sánchez P, Lavado-García JM, Canal-Macías ML, 
Gómez-Zubeldia MA, Roncero-Martín R, Pedrera-Zamorano 
JD. Ultrasound bone mass in schizophrenic patients on anti-
psychotic therapy. Hum Psychopharmacol 2009;24:49-54.
45. Sugawara N, Yasui-Furukori N, Fujii A, Saito M, Sato Y, 
Nakagami T, et al. No association between bone mass and 
prolactin levels among patients with schizophrenia. Hum 
342 J. Lally, et al.
Psychopharmacol 2011;26:596-601.
46. Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone 
mineral density and prolactin associations in patients with 
chronic schizophrenia. Schizophr Res 2003;59:17-18.
47. Hallahan B, Lyons D, Doyle P. Bone mineral density and gen-
eral health of long-term residential psychiatric inpatients. Ir J 
Psychol Med 2008;25:95-99.
48. Kim J, Kim S, Kim S, Choi S. Menstrual irregularities and sex 
hormones in female patients treated with conventional anti-
psychotics for more than 5 years. Clin Psychopharmacol 
Neurosci 2010;8:21-25.
49. Kinon BJ, Liu-Seifert H, Stauffer VL, Jacob J. Bone loss asso-
ciated with hyperprolactinemia in patients with schizo-
phrenia. Clin Schizophr Relat Psychoses 2013;7:115-123.
50. Lally J, Gardner-Sood P, Firdosi M, Iyegbe C, Stubbs B, 
Greenwood K, et al. Clinical correlates of vitamin D defi-
ciency in established psychosis. BMC Psychiatry 2016;16:76.
51. Lally J, Ajnakina O, Singh N, Gardner-Sood P, Stubbs B, 
Stringer D, et al. Vitamin D and clinical symptoms in First 
Episode Psychosis (FEP): a prospective cohort study. 
Schizophr Res 2019;204:381-388.
52. Crews M, Lally J, Gardner-Sood P, Howes O, Bonaccorso S, 
Smith S, et al. Vitamin D deficiency in first episode psychosis: 
a case-control study. Schizophr Res 2013;150:533-537.
53. Savvidis C, Tournis S, Dede AD. Obesity and bone meta-
bolism. Hormones (Athens) 2018;17:205-217.
54. Watanabe SY, Iga J, Numata S, Nakataki M, Tanahashi T, 
Itakura M, et al. Association study of fat-mass and obe-
sity-associated gene and body mass index in Japanese patients 
with schizophrenia and healthy subjects. Clin 
Psychopharmacol Neurosci 2012;10:185-189.
55. Thomson D, Berk M, Dodd S, Rapado-Castro M, Quirk SE, 
Ellegaard PK, et al. Tobacco use in bipolar disorder. Clin 
Psychopharmacol Neurosci 2015;13:1-11.
56. de Leon J, Diaz FJ. A meta-analysis of worldwide studies dem-
onstrates an association between schizophrenia and tobacco 
smoking behaviors. Schizophr Res 2005;76:135-157.
57. González-Blanco L, Greenhalgh AMD, Garcia-Rizo C, 
Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin concen-
trations in antipsychotic-naïve patients with schizophrenia 
and related disorders: a meta-analysis. Schizophr Res 2016; 
174:156-160.
58. Stewart A, Kumar V, Reid DM. Long-term fracture prediction 
by DXA and QUS: a 10-year prospective study. J Bone Miner 
Res 2006;21:413-418.
59. Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen IE, et al. 
Meta-analysis: accuracy of quantitative ultrasound for identi-
fying patients with osteoporosis. Ann Intern Med 2006;144: 
832-841.
